SG11202100371RA - Lyophilized pharmaceutical compositions for naked dna gene therapy - Google Patents
Lyophilized pharmaceutical compositions for naked dna gene therapyInfo
- Publication number
- SG11202100371RA SG11202100371RA SG11202100371RA SG11202100371RA SG11202100371RA SG 11202100371R A SG11202100371R A SG 11202100371RA SG 11202100371R A SG11202100371R A SG 11202100371RA SG 11202100371R A SG11202100371R A SG 11202100371RA SG 11202100371R A SG11202100371R A SG 11202100371RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- gene therapy
- naked dna
- lyophilized pharmaceutical
- dna gene
- Prior art date
Links
- 102000053602 DNA Human genes 0.000 title 1
- 108091061960 Naked DNA Proteins 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700655P | 2018-07-19 | 2018-07-19 | |
| PCT/US2019/042702 WO2020018969A1 (en) | 2018-07-19 | 2019-07-19 | Lyophilized pharmaceutical compositions for naked dna gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100371RA true SG11202100371RA (en) | 2021-02-25 |
Family
ID=69162312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100371RA SG11202100371RA (en) | 2018-07-19 | 2019-07-19 | Lyophilized pharmaceutical compositions for naked dna gene therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11554179B2 (en) |
| EP (1) | EP3823677A4 (en) |
| JP (1) | JP7212230B2 (en) |
| KR (1) | KR20210027493A (en) |
| CN (1) | CN112088017B (en) |
| AU (1) | AU2019305221A1 (en) |
| BR (1) | BR112021000722A2 (en) |
| CA (1) | CA3106297A1 (en) |
| SG (1) | SG11202100371RA (en) |
| WO (1) | WO2020018969A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210027493A (en) * | 2018-07-19 | 2021-03-10 | 주식회사 헬릭스미스 | Freeze-dried pharmaceutical composition for naked DNA gene therapy |
| CN110530755B (en) * | 2019-09-09 | 2021-06-08 | 江苏省原子医学研究所 | Method for testing vacuum freeze drying time of photosensitive medicine and application |
| KR20230141965A (en) * | 2022-03-24 | 2023-10-10 | 주식회사 헬릭스미스 | Liquid formulation pharmaceutical composition comprising plasmid DNA |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
| DE69131069T2 (en) | 1990-07-13 | 1999-07-15 | Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido | PLASMID THE DNA ENCODING THE AMINO ACID SEQUENCE OF TCF-II CONTAINS, TRANSFORMED CELL AND PRODUCTION OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH THEIR USE |
| US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
| US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
| US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| JP3927248B2 (en) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | HGF lyophilized formulation |
| ES2240999T3 (en) | 1995-08-29 | 2005-10-16 | Anges Mg, Inc. | MEDICINAL CONTAINING A GENE OF HGF. |
| US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| ZA973642B (en) | 1996-04-26 | 1997-11-25 | Merck & Co Inc | DNA vaccine formulations. |
| CN1267331A (en) | 1997-05-06 | 2000-09-20 | 加利福尼亚大学董事会 | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes |
| AU1940599A (en) | 1997-12-23 | 1999-07-12 | Merck & Co., Inc. | Dna pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| US6387695B1 (en) | 1997-12-23 | 2002-05-14 | Merck & Co., Inc. | DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| US20040228834A1 (en) | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
| CA2322559C (en) | 1998-03-09 | 2012-07-17 | St. Elizabeth's Medical Center | Compositions and methods for modulating vascularization |
| DK1061955T3 (en) | 1998-03-13 | 2005-07-04 | Wyeth Corp | Polynucleotide composition, method of preparation and use thereof |
| CA2322232A1 (en) | 1998-03-13 | 1999-09-16 | American Home Products Corporation | Lyophilized polynucleotide composition, method of preparation, and uses thereof |
| US7276359B1 (en) | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| WO2001032220A1 (en) | 1999-10-29 | 2001-05-10 | Medgene Bioscience, Inc. | Gene therapy for diabetic ischemic disease |
| EA008538B1 (en) | 1999-11-05 | 2007-06-29 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Techniques and compositions for treating cardiovascular disease by in vivo gene dilivery |
| US20030171287A1 (en) | 2000-06-27 | 2003-09-11 | Ryuichi Morishita | Medicinal compositions for angiogenic therapy |
| US20030176347A1 (en) | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
| CN1150035C (en) | 2000-12-21 | 2004-05-19 | 中国人民解放军军事医学科学院放射医学研究所 | Recombination plasmid and application in disease prevention and control |
| KR100562824B1 (en) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor |
| MXPA05003771A (en) | 2002-10-09 | 2005-06-08 | Pfizer Prod Inc | Stabilized naked dna compositions. |
| WO2004060059A2 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| US20050164208A1 (en) | 2004-01-22 | 2005-07-28 | Paul Poulin | Storage of genetic information |
| EP2007883B1 (en) * | 2006-04-20 | 2011-12-28 | Wyeth LLC | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| EP2022853A4 (en) | 2006-05-17 | 2010-03-10 | Yoshiyuki Koyama | Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof |
| US20090202606A1 (en) | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
| RU2470995C2 (en) | 2008-04-09 | 2012-12-27 | Вайромед Ко., Лтд. | Lyophilised dna compounds for increased plasmid dna expression |
| EP2510100B1 (en) * | 2009-12-09 | 2017-10-11 | CureVac AG | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2011069529A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP3257525A3 (en) | 2009-12-22 | 2018-02-28 | Celldex Therapeutics, Inc. | Vaccine compositions |
| EP2968460B1 (en) | 2013-03-11 | 2021-01-06 | Amgen Inc. | Protein formulations |
| CN107073078B (en) * | 2014-09-26 | 2021-07-06 | 赫利世弥斯株式会社 | Composition for preventing or treating peripheral arterial disease using hepatocyte growth factor and stromal cell derived factor 1 alpha |
| WO2019078586A1 (en) * | 2017-10-18 | 2019-04-25 | Viromed Co., Ltd. | Treatment of neuropathy with dna construct expressing hgf isoforms with reduced interference from gabapentinoids |
| EP3823982A4 (en) * | 2018-07-17 | 2022-04-13 | Helixmith Co., Ltd | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
| CA3106078A1 (en) * | 2018-07-17 | 2020-01-23 | Junghun Lee | Treatment of neuropathy with dna constructs expressing igf-1 isoforms |
| KR20210027493A (en) * | 2018-07-19 | 2021-03-10 | 주식회사 헬릭스미스 | Freeze-dried pharmaceutical composition for naked DNA gene therapy |
| US20220177921A1 (en) * | 2018-08-27 | 2022-06-09 | BioViva USA, Inc. | Gene therapy using genetically modified viral vectors |
| RU2730664C2 (en) * | 2018-12-27 | 2020-08-24 | Селл энд Джин Терапи Лтд | Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene selected from group of genes ang, angpt1, vegfa, fgf1, hif1α, hgf, sdf1, klk4, pdgfc, prok1, prok2 to increase expression level of said target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-ang, or escherichia coli scs110-af/vtvaf17-angpt1, or escherichia coli scs110-af/vtvaf17-vegfa, or escherichia coli scs110-af/vtvaf17-fgf1, or escherichia coli scs110-af/vtvaf17-hif1α, or escherichia coli scs110-af/vtvaf17-hgf, or escherichia coli scs110-af/vtvaf17-sdf1, or escherichia coli scs110-af/vtvaf17-klk4, or escherichia coli scs110-af/vtvaf17-pdgfc, or escherichia coli scs110-af/vtvaf17-prok1, or escherichia coli scs110-af/vtvaf17-prok2, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector |
-
2019
- 2019-07-19 KR KR1020217005130A patent/KR20210027493A/en unknown
- 2019-07-19 WO PCT/US2019/042702 patent/WO2020018969A1/en active Application Filing
- 2019-07-19 JP JP2021502948A patent/JP7212230B2/en active Active
- 2019-07-19 CA CA3106297A patent/CA3106297A1/en active Pending
- 2019-07-19 EP EP19838143.6A patent/EP3823677A4/en active Pending
- 2019-07-19 AU AU2019305221A patent/AU2019305221A1/en active Pending
- 2019-07-19 SG SG11202100371RA patent/SG11202100371RA/en unknown
- 2019-07-19 BR BR112021000722-9A patent/BR112021000722A2/en unknown
- 2019-07-19 CN CN201980013146.0A patent/CN112088017B/en active Active
- 2019-07-19 US US16/517,323 patent/US11554179B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7212230B2 (en) | 2023-01-25 |
| CN112088017B (en) | 2023-11-21 |
| BR112021000722A2 (en) | 2021-05-04 |
| AU2019305221A1 (en) | 2021-02-18 |
| EP3823677A1 (en) | 2021-05-26 |
| CN112088017A (en) | 2020-12-15 |
| JP2022500354A (en) | 2022-01-04 |
| US11554179B2 (en) | 2023-01-17 |
| US20200023075A1 (en) | 2020-01-23 |
| EP3823677A4 (en) | 2022-06-01 |
| KR20210027493A (en) | 2021-03-10 |
| CA3106297A1 (en) | 2020-01-23 |
| WO2020018969A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913505WA (en) | Truncated crispr-cas proteins for dna targeting | |
| ZA201806544B (en) | Closed-ended linear duplex dna for non-viral gene transfer | |
| PT3616720T (en) | Pharmaceutical composition for cancer treatment | |
| HK1246191A1 (en) | Pharmaceutical compositions for combination therapy | |
| ZA201906613B (en) | Pharmaceutical compositions for combination therapy | |
| EP3280421A4 (en) | Pharmaceutical compositions for combination therapy | |
| HK1254645A1 (en) | Lyophilized pharmaceutical compositions | |
| ZA201905510B (en) | Pharmaceutical compositions for combination therapy | |
| SG11202100371RA (en) | Lyophilized pharmaceutical compositions for naked dna gene therapy | |
| IL315071A (en) | Modified oligonucleotides and pharmaceutical compositions | |
| IL264593A (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL289213A (en) | Pharmaceutical composition for treating tumor | |
| IL265684A (en) | Wt1 targeting dna vaccine for combination therapy | |
| GB201905301D0 (en) | Gene therapy | |
| GB201707212D0 (en) | Gene therapy for ciliopathies | |
| IL268708B (en) | Pharmaceutical compositions for combination therapy | |
| GB201800370D0 (en) | Anionic nanocomplexes for nucleic acid delivery | |
| HUE051563T2 (en) | Pharmaceutical composition for preventing or treating cancer | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| PL3908321T3 (en) | Pharmaceutical composition | |
| EP3363464A4 (en) | Pharmaceutical composition for treating cancer comprising rna oligonucleotide | |
| GB201901989D0 (en) | Pharmaceutical combinations | |
| EP3116513A4 (en) | Pharmaceutical compositions comprising rna and use for treating cancer | |
| GB201906487D0 (en) | DNA Marker |